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Abstract
Background: Recent cancer genome studies on many human cancer types have relied on multiple molecular high-
throughput technologies. Given the vast amount of data that has been generated, there are surprisingly few
databases which facilitate access to these data and make them available for flexible analysis queries in the broad
research community. If used in their entirety and provided at a high structural level, these data can be directed into
constantly increasing databases which bear an enormous potential to serve as a basis for machine learning
technologies with the goal to support research and healthcare with predictions of clinically relevant traits.
Results: We have developed the Cancer Systems Biology Database (CancerSysDB), a resource for highly flexible
queries and analysis of cancer-related data across multiple data types and multiple studies. The CancerSysDB can be
adopted by any center for the organization of their locally acquired data and its integration with publicly available
data from multiple studies. A publicly available main instance of the CancerSysDB can be used to obtain highly
flexible queries across multiple data types as shown by highly relevant use cases. In addition, we demonstrate how
the CancerSysDB can be used for predictive cancer classification based on whole-exome data from 9091 patients in
The Cancer Genome Atlas (TCGA) research network.
Conclusions: Our database bears the potential to be used for large-scale integrative queries and predictive
analytics of clinically relevant traits.
Background
Large-scale cancer genome studies based on Next-
Generation Sequencing (NGS) technology have enabled
extensive research on tumorigenesis and treatment ratio-
nales [14]. The amount of data that has been generated
and made available contrasts its limited accessibility to
the research community. There is an increasing demand
for customized queries to the data in a way that is ac-
cessible to scientists and physicians without any know-
ledge in bioinformatics. Genomic data from studies in
The Cancer Genome Atlas (TCGA) research network
obtained through the Genomic Data Commons (GDC)
Data Portal (https://portal.gdc.cancer.gov) are available
for multiple molecular layers and are provided in
formats processed through appropriate software packages
for the analysis of the raw data for every data type. The size
of these processed data is orders of magnitude smaller than
the raw data, in particular for whole-genome sequencing
experiments, but provided in a diverse range of file formats
in which the data are variably well structured. Thus, it is
particularly challenging to transform these file-based data
into a structure which allows a technically reasonable way
to integrate data obtained by multiple technologies with
manually curated data recorded in a clinical context. This
underlines the need for highly flexible database structures
which are suitable to model data from TCGA studies, but
are generic enough to also combine TCGA data with locally
acquired data obtained in a clinical context.
We present here the newly developed Cancer Systems
Biology Database (CancerSysDB) portal which allows
integrated analyses across multiple data types and across
multiple cancer cohorts from The Cancer Genome Atlas
(TCGA) research network, but also from locally ac-
quired data in a clinical context. With its current
* Correspondence: peter.frommolt@uni-koeln.de
2Bioinformatics Facility, CECAD Research Center, University of Cologne,
Cologne, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Krempel et al. BMC Bioinformatics  (2018) 19:156 
https://doi.org/10.1186/s12859-018-2157-7
workflows, our system allows fast integrative analysis of
whole-exome (WXS) and transcriptome (RNA-Seq)
sequencing data. By making use of standardized JSON-
based meta data formats, the CancerSysDB can be
integrated into existing analysis workflows. The Cancer-
SysDB enables highly structured organization of data
from multi-OMICS technologies and makes them ac-
cessible for big data analytics on the entirety of all data
ever processed on a particular site. Conceptually, this
includes the prediction of clinically relevant parameters
such as therapeutic response from existing pharmacoge-
nomic data in the CancerSysDB.
Methods
Implementation
The CancerSysDB was written in Groovy on the
Grails framework based on the JVM stack which bun-
dles state-of-the-art web frameworks behind a simple
interface. The CancerSysDB is a web application
which needs a database instance and an application
server and can run Linux shell scripts and other exe-
cutables from a command line. The data source is
behind a hibernate facade keeping the system inde-
pendent from the database implementation used and
the optimization in the background. The delivered
versions are based on a docker file to automatically
build an environment and run the database applica-
tion for personal use. A demo instance can be used
to make personalized queries to the database using
publicly available TCGA data. The source code of the
CancerSysDB is available on GitHub (https://github.
com/RRZK/CancerSysDB).
The system can be configured to run in two different
modes. The public mode can be used to query publicly
available data without any login. The publicly available
main instance of the CancerSysDB available on http://
cancersys.uni-koeln.de is running in public mode and
provides access to data on 11,410 patients from the Can-
cer Genome Atlas (TCGA) research network. This
instance includes data on somatic mutations (based on
WXS data), differential gene expression (based on com-
parative RNA-Seq analysis between tumors and tissue-
derived normals), somatic copy number alterations
(based on Affymetrix SNP 6.0 microarrays) as well as all
clinically derived annotations of the TCGA patient data.
These data types provide a powerful basis for arbitrary
queries defined by the user. All TCGA data types pro-
vided through the CancerSysDB are open access data
and can be obtained from the TCGA data portal without
exclusive access. Users have to adhere to the TCGA data
access policies that apply to these open access data
(https://gdc.cancer.gov/access-data/data-access-policies).
On the other hand, the private mode requires a login for
any interaction. This mode is strongly recommended if
you are working with restricted data. The University of
Cologne is operating a private mode instance of the
CancerSysDB for the organization of genomic data from
in-house studies. It is used in combination with the
recently published cancer genomics data processing
workflow system QuickNGS Cancer [1] which extends
our NGS bioinformatics suite QuickNGS [15] and allows
highly scalable and standardized analysis of cancer NGS
data with minimum hands-on analysis time. Various fea-
tures of the CancerSysDB are compared to those of
other cancer genome data integration tools in Table 1.
Data model and queries
The maintainer of a CancerSysDB instance can describe
the connection between data and the main structure of
the application in JSON files to bring the context struc-
ture of data into the database. The database consists of
four main data types:
 Structural data manages the patients and samples,
 Molecular data is derived from cancer genome
analysis,
 Clinical data is associated to the clinical course of a
patient’s disease,
 Genomic annotation provides information on genes
and meta data about these genes.
Table 1 Comparison of various features of the CancerSysDB with those of other cancer genomics data integration tools
CancerSysDB TCGAbiolinks RTCGA cBio portal
GUI Web framework based
on Groovy/Grails
Based on Shiny None Web framework based
on Spring Java
Query schema Hibernate R scripting R scripting SQL
Data upload Parametrized CSV
file upload
Direct access to
GDC through API
Data packages available
on Bioconductor
CSV files plus meta file
Query definition JSON-based Combination of
R commands
Combination of R commands REST-based API
Portability Native Docker implementation Hosted on Bioconductor Hosted on Bioconductor Hosted on GitHub
Programming skills
required
No Yes Yes No
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The data model and principles how to develop data-
base queries is further described on GitHub at https://
github.com/RRZK/CancerSysDB/tree/master/web-app/
data/Workflows . Data can be uploaded through the API
or manually with the web front end. The API enables
automated uploads from processing infrastructures like
high performance computing (HPC) environments. A
collection of Python scripts for upload automation is
delivered with the database. We are using these scripts
to link the analysis workflows on the QuickNGS Cancer
pipeline to the CancerSysDB. The internal design of the
web application empowers the maintainer to easily extend
the data model, extend the import behavior and integrate
custom data structures.
The maintainer of an instance of the CancerSysDB is
provided with a fully controllable environment for the
development of custom workflows. A custom workflow
can be described in a JSON file and extended with ana-
lysis scripts and static data in a zip file which can be
dynamically uploaded into the database (documentation
available on the GitHub). The actual data is retrieved
using queries written in the Hibernate Query Language
(HQL) and the results of the queries are saved as CSV
files in order to increase reproducibility on a dynamically
updated database. Subsequent computations can rely on
arbitrary executables in a Linux environment. The con-
tainer architecture provides the encapsulation for the
workflows. To control the command line based execu-
tion, packages and libraries can be installed on creation
of the docker container or wrapped directly into the files
to be executed by the workflow.
Data preparation
All TCGA data were obtained as level 3 data from the
Legacy Archive of The Cancer Genome Atlas (TCGA)
data portal. Data on somatic mutations were based on
whole-exome sequencing with MAF files obtained from
the Firehose pipeline of the Genome Data Analysis
Fig. 1 Analysis results for workflows splitting multiple TCGA cohorts into TP53-mutant and non-mutant patients: a Overall survival is significantly different
between TP53-mutant (red curve) and non-mutant patients (black curve) with a more favorable for non-mutant patients (gain in median survival: 2066 days,
p < 0.0001, n = 9444). b The distribution of the mutations types in lung adenocarcinoma is strongly shifted towards an increase of G > T transversions in
TP53 mutant compared to non-mutant patients (p = 0.0006, n = 584). c Genomic stability is quantified in terms of the overall size of somatic copy number
alterations (sCNA) compared between tumor and normal. sCNA are considered as genomic amplifications above a level of 3 and as genomic deletions
below a level of 1 for the signal ratio between tumor and paired normal sample. The difference between TP53 mutant and non-mutant patients is highly
significant in glioblastoma multiforme (p = 0.0132, n = 379)
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Center (GDAC) at the Broad Institute. Data on somatic
copy number alterations were based on the SNP 6.0
microarray platform (Affymetrix Inc., CA, USA) given as
genomic segments of equal copy number derived from
the Circular Binary Segmentation (CBS) algorithm [8].
For gene expression analysis, raw RNA-Seq read counts
were re-processed and compared between tumor tissues
and tissue-derived normal samples using version 1.21.1
of the DESeq2 algorithm and its implementation as an R
package [6]. These tissue-derived normal controls are
available from only a minority of the patients in TCGA,
but we consider them more suitable for a comparative
tumor/normal analysis than the blood-derived normals
existing for most patients. The currently existing work-
flows were implemented using version 3.3.3 of the func-
tional statistics language R (http://www.r-project.org).
The random forest workflow was implemented with the
R package ‘randomForest’, version 4.6–12.
Results and discussion
In order to demonstrate how the CancerSysDB can help to
obtain analysis results of immediate relevance for research
projects or clinical prognosis, we showcase the analytical
power by three example queries, by one machine learning
workflow on the CancerSysDB and by an interactive work-
flow of visualizing mitochondrial pathways. The results of
these showcases can be reproduced using the query and
analysis source code provided in Additional file 1.
TP53-dependent analysis of overall survival, genome
stability, and mutation types
The tumor suppressor gene TP53 is the most frequently
deleted and mutated gene across all tumor types [3]. In
the TCGA cancer cohorts, its mutation rate is highly
variable and ranges up to > 75% in some cancer types
[16]. The CancerSysDB enables comparative genomic
analyses of patients with and without mutations in
TP53 by employing three different query workflows
which we operate across > 11,000 patients from 33
TCGA studies.
 Overall survival depending on mutation status:
Across all TCGA cohorts, patients with a mutation
in TP53 show an unfavorable prognosis regarding
overall survival compared to TP53 wild type patients
(p < 0.0001, n = 9444; Fig. 1a; Table 2a).
 Transversions and transitions depending on
mutation status: The somatic mutational landscape
of patients with lung adenocarcinoma exhibits a
significant shift towards G > T transversions when
compared between patients with and without
mutations in TP53 (p = 0.0006, n = 584; Fig. 1b;
Table 2b). G > T transversions have been shown to
be induced by oxidative stress in lung cancers of
tobacco smokers [12]. Their enrichment in patients
with mutated TP53 is likely caused by the impaired
induction of apoptosis upon these exogenic
damages.
Table 2 Results of TP53-dependent analysis of genomic and clinical characteristics
(a)
Patients Events 5-year survival
rate [%]
Median survival 95% CI
TP53 mutant 3772 1237 47.4 1670 [1526; 1818]
TP53 non-mutant 5672 1128 66.9 3736 [3262; 4267]
(b)
Patients CNAs [Mb]
TP53 mutant 133 74.5
TP53 non-mutant 246 50.5
(c)
TP53 ATM
VarType All Mutant
[%] (n = 320)
Non-mutant
[%] (n = 265)
p-value Mutant
[%] (n = 49)
Non-mutant
[%] (n = 536)
p-value
A > C or T > G 3.5 3.3 3.6 < 0.0001 3.9 3.4 0.2160
A > G or T > C 9.9 9.2 10.7 < 0.0001 9.6 9.9 0.7695
A > T or T > A 8.1 8.4 7.8 0.0005 8.6 8.1 0.4584
C > G or G > C 13.6 13.9 13.1 < 0.0001 13.2 13.6 0.3790
C > T or G > A 32.7 30.0 36.0 < 0.0001 28.6 33.0 0.5121
G > T or C > A 32.3 35.2 28.8 0.0001 36.0 32.0 0.4940
Krempel et al. BMC Bioinformatics  (2018) 19:156 Page 4 of 10
 Genomic complexity depending on mutation status:
Among the patients with glioblastoma multiforme,
those with TP53 mutations are characterized by, on
average, stronger genomic instability than the TP53
wild type patients (p = 0.0132, n = 379; Fig. 1c; Table
2c). This general loss of genomic stability in TP53-
mutated patients can be attributed to the role of
TP53 as a mediator of apoptosis in response to som-
atically acquired DNA damage of cancer cells and
has been described in previous studies [7].
Technically, the workflows start with database queries
for the TCGA barcodes of the patients with and without
TP53 mutations. Subsequent queries obtain the overall
survival of all patients, the overall size of genomic copy
number aberrations in glioblastoma multiforme, and a
list of all mutations in the cohort of patients with lung
adenocarcinoma. These query results are stored as CSV
files on the CancerSysDB server and are processed
through workflow analysis scripts to restructure, analyze
and visualize the data. The scripts for this TP53-
dependent analysis of TCGA data were written in the
functional statistics language R.
Prediction of cancer types with random forests
In order to demonstrate the potential of our database
for predictive analytics of clinically relevant traits, we
have evaluated a workflow for the classification of a yet
Table 3 Classes of carcinomas used for random forest prediction of cancer types
Class name TCGA cohorts Sample size
Total Training set Test set
Adrenal gland Adrenocortical carcinoma (ACC) 271 179 92
Pheochromocytoma and paraganglioma (PCPG)
Bladder Urothelial carcinoma (BLCA) 411 272 139
Brain Lower grade glioma (LGG) 515 340 175
Breast Breast invasive carcinoma (BRCA) 1077 711 366
Gastrointestinal Esophageal carcinoma (ESCA) 1237 817 420
Stomach adenocarcinoma (STAD)
Colon adenocarcinoma (COAD)
Rectum adenocarcinoma (READ)
Cholangiocarcinoma (CHOL)
Head & Neck Head and neck squamous cell carcinoma (HNSC) 590 390 200
Uveal melanoma (UVM)
Hematologic Acute myeloid leukemia (LAML) 321 212 109
Diffuse large B-cell lymphoma (DLBC)
Thymoma (THYM)
Kidney Kidney Chromophobe (KICH) 738 488 250
Renal clear cell carcinoma (KIRC)
Renal papillary cell carcinoma (KIRP)
Liver Hepatocellular carcinoma (LIHC) 321 212 109
Ovary Ovarian serous cystadenocatcinoma (OV) 437 289 148
Pancreas Pancreatic adenocarcinoma (PAAD) 184 122 62
Prostate Prostate adenocarcinoma (PRAD) 498 329 169
Skin Cutaneous melanoma (SKCM) 104 69 35
Testis Testicular germ cell tumors (TGCT) 150 99 51
Thoracic Lung adenocarcinoma (LUAD) 1143 755 388
Lung squamous cell carcinoma (LUSC)
Mesothelioma (MESO)
Thyroid Thyroid carcinoma (THCA) 496 327 169
Uterus Uterine carcinosarcoma (UCS) 598 395 203
Uterine corpus endometrial carcinoma (UCEC)
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uncharacterized sample into one of the cancer types
available in the CancerSysDB. This workflow can be ap-
plied, for instance, to predict the primary site of a tumor
from a metastatic tissue specimen of unknown origin.
The workflow is basically composed of two steps:
 In the training phase, a random forest consisting of
1000 trees is trained on all data available in the
CancerSysDB. The workflow is composed of an
HQL query with subsequent submission of the
query results to a high-performance compute clus-
ter. In order to control for the relatively strong im-
balance in the class sizes, the workflow was
implemented using a stratified sampling approach in
the random forest training procedure. The random
forest is then trained in 100 parallel processes with
10 trees in each process. Subsequently, the forest is
loaded back into the CancerSysDB. The entire pro-
cedure must be repeated any time new data is being
uploaded into the CancerSysDB. Random forests
were chosen because of their good adaption to (bin-
ary) mutation data and their convenience in
parallelization.
 In the prediction phase, a list of mutations of a
yet unclassified sample can be uploaded into the
CancerSysDB and is classified according to the
random forest obtained in the training phase. As
usual, the classification is determined by a
majority vote between the 1000 classification trees
in the forest.
In the current workflow on the public instance, the
training phase was carried out on data from 9091 pa-
tients in the CancerSysDB. To demonstrate that the pre-
dictions produced in this workflow are of sufficient
accuracy to make them practically applicable, we split
the 9091 patients in a training set of 6006 patients (66.
6% in each cohort) and evaluated the predictions in a
test set comprising 3085 patients (33.3% in each cohort;
Table 3). Out of these 3085 patients in the test set, 1521
(49.3%) were assigned to the correct class (Fig. 2),
whereas a random guess of the class would have
produced a correct class assignment in only 182 cases
(5.9%). Further evaluations of the workflow performance
show that the success rate of the predictions does not
increase with the number of trees nor the number of
variables evaluated at each split, but strongly depends on
the number of training samples (Additional file 2: Figure
S1). In particular, Additional file 2: Figure S1c suggests
that the accuracy could potentially be improved given a
Fig. 2 Results of a cross validation of the random forest prediction of cancer types in the CancerSysDB. The predictions are based on a random
forest learned on the training set comprising 6006 patients from 30 TCGA studies (Table 2). Displayed are the predictions of the classes in the
3085 patients in the training set. The accuracy strongly varies across the particular subclasses, but sums up to a total of 1521 correctly classified
patients (49.3%)
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Fig. 3 (See legend on next page.)
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constantly growing amount of data in the CancerSysDB.
However, we assume that the accuracy could be most
stronly improved when including additional data types
such as gene expression to the predictive algorithms.
Analyzing TCA-cycle genes in kidney renal papillary cell
carcinoma (KIRP)
We have implemented one interactive workflow, which
allows users to perform an in-depth analysis of specific
groups of genes or pathways. For the public instance of
the CancerSysDB, we have chosen a set of mitochon-
drial functions. The interactive workflow consists of a
bee swarm scatter plot displaying the differential ex-
pression (log2-fold change) of all genes in a selected
pathway, as well as an interactive dashboard, where
users can select the desired features for data display on
the bee swarm scatter plot (see Additional file 3: Figure
S2). Pathways to be shown can be selected on the right-
hand side of the scatter plot. Features that can be
chosen include the stage of the tumor, gender of the pa-
tients, as well as vital status. Differential expression is
averaged over all individuals associated with a specific
feature. If one feature is selected (e.g. stage of tumor)
and the user hovers over any other fields of the dash-
boards, the data presented in the scatter plot are fil-
tered accordingly. Hovering over one of the stages will
give information on gender and vital status of all
subjects within this stage (see for instance Additional
file 3: Figure S2b, where hovering over Stage IV returns
the information on gender (4 males) and vital status (3
alive, 1 dead) of all subjects of this tumor stage). Hover-
ing over one of the other dashboards will change the
data for averaging accordingly. For instance, when
hovering over FEMALE, data are averaged over 10 pa-
tients in two stages (Stage I and Stage III), with 2
individuals with the vital status Dead and 8 ones with
vital status Alive.
We have used this workflow to observe the dynamics
of the TCA pathway in KIRP (kidney renal papillary cell
carcinoma) patients during tumor progression. We ob-
served a strong down-regulation of the Succinate-CoA
ligase subunits SUCLG1 and SUCLG2 in Stage IV KIRP
patients (Fig. 3 and Table 4), which is independent of
the vital status of the patients. We have not observed
this specific down-regulation of both Succinate-CoA lig-
ase subunits for any stage-specific cohort of any other
tumor type imported from TCGA. An equally strong
down-regulation of both subunits could only be ob-
served for two sarcoma patients where no staging is
done (SARC cohort in TCGA, data not shown).
Succinate-CoA ligase (SUCL) catalyses the conversion
of succinyl-CoA and ADP or GDP to succinate and ATP
or GTP. Substrate specificity is determined by the beta-
subunit of the complex, which is either SUCLA2 (ATP)
or SUGLG2 (GTP), while the alpha-subunit (SUCGL1)
does not differ for either substrate [4]. SUCLG2 is pre-
dominately expressed in anabolic tissues such as liver or
kidney [4, 5]; for these tissues, GTP is more important,
as it is involved in processes such as gluconeogenesis or
protein synthesis. Mutations of SUCLG1 lead to loss of
SUCLG1 protein expression and subsequently to deple-
tion of mtDNA; clinically, affected individuals suffer
from severe acidosis and lactic aciduria [9]. Expression
changes of SUCLG1 and 2 mRNA [2, 13], as well as
protein [11, 17] were also identified in several studies as
potential markers for kidney cancers. More notably,
down-regulation of SUCLG2 protein levels are
furthermore indicative for late stages in clear cell renal
carcinomas [10].
Conclusions
The CancerSysDB enables highly flexible analyses of
cancer data across multiple OMICS data types and clin-
ical data. We have demonstrated that the system can be
used for cross-data type queries with clinically relevant
information on prognosis, genome stability and muta-
tion types of patients with and without mutations in the
tumor suppressor TP53. In addition, we have given an
example how machine learning technology on only one
single data type (somatic mutations) can be used to
achieve confident predictions of clinically relevant traits.
Finally, we have provided an example how our system
(See figure on previous page.)
Fig. 3 In-depth analysis of the dynamics of the TCA pathway in KIRP cancer patients. Interactive view bee-swarm scatter plot on the Tricarboxylic
acid cycle (TCA) pathway from KIRP cancer patients is shown. The log2-fold changes are averaged for patients according to tumor grade
(Stage I-IV). The dashboard gives the number of patients per grade and allows for further filtering according to gender or vital status (see
also Additional file 2: Figure S1). a The SUCLG1 gene is selected (pink bubble in bee-swarm scatter plot). b The SUCLG2 gene is selected.
Both genes show a strong, averaged down-regulation in Stage IV KIRP cancer patients (see Table 4 for averaged log2-fold changes)
Table 4 Averaged log2-fold changes of SUCLG1 and SUCLG2
mRNAs in different tumor stages of KIRP cancer patients
Stage #
Patients
Female/
Male
Alive/
Dead
SUCLG1 SUCLG2
log2 FC p-value log2 FC p-value
I 15 5 / 10 13 / 2 −0.473 0.132 −0.338 0.307
II 1 0 / 1 1 / 0 −1.163 0.082 0.137 0.431
III 11 5 / 6 8 / 3 −0.835 0.018 −0.760 0.028
IV 4 0 / 4 3 / 1 −1.975 0.066 −1.664 0.054
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can be used as a platform for interactive analysis of dif-
ferent OMICS data types. The information provided by
the TCGA data currently used in the public instance of
the CancerSysDB is still very limited compare to the
amount of data that can be expected in the near future
when genomic analyses in a clinical context are becom-
ing more and more a routine analysis. The CancerSysDB
offers an appropriate framework to employ machine
learning algorithms on much larger data volumes to pre-
dict, for instance, the overall survival of a patient and
the response to a particular therapy given a patient’s mo-
lecular background.
Additional files
Additional file 1: The source code of the database queries and
workflow scripts for the three use cases reported in the paper. The results
can be reproduced using the query results and analysis scripts provided.
File query1.csv contains the barcodes of all samples for which mutation
data do exist. File query2.csv contains the barcodes of all samples which
carry a mutation in the gene of interest. Finally, query3.csv contains the
survival data (according to Fig. 1a), a list of all mutations of patients in
the cohort of interest (according to Fig. 1b), or a list of all genomic
segments with aberrant copy number in the cohort of interest (according
to Fig. 1c). There are small discrepancies between the number of patients
with mutation data and the number of patients with survival data (Fig.
1a) and copy number data (Fig. 1c). (ZIP 4981 kb)
Additional file 2: Figure S1 Overall success rate of the prediction of
tumor types by random forests depending on (a) the number of samples
per stratum in the random forest, (b) the number of variables picked
randomly for each tree in the forest and (c) the number of trees learned
in the forest. Importantly, the accuracy is increasing monotonically with
the number of samples, indicating that the overall strategy is suitable, in
particular, for a database with continuously growing amounts of data. In
contrast, the success rate does not so much depend on the parameters
chosen for the training phase of the random forest. (PNG 34 kb)
Additional file 3: Figure S2 Interactive workflow of mitochondrial
pathways. Shown is the Tricarboxylic acid cycle (TCA) pathway for KIRP
cancer patients. The central view of this workflow is a bee-swarm scatter-
plot, which contains the averaged log2-fold changes of patient groups
according to either tumor stage, gender or vital status. Each dot is repre-
sents the averaged log2-fold change of one gene that has been assigned
to the chosen function. Functions can be selected on the right-hand side
of the scatter plot. The dashboard below the scatter plot can be used to
change the averaging according to a different feature ((a), which shows
averaging according to stage), to display information on the composition
of the selected feature ((b), which informs the user that all individuals of
stage II, which was hovered over in this case, are male and that one indi-
vidual is dead, while three of the patients are alive); or to further select
individual patients and thus modify the averaging shown in the scatter
plot ((c), where only female patients were chosen for stage-dependent
averaging; as female patient data are only available for two stages (I and
III), the scatter plot is changed accordingly). (PNG 679 kb)
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